POET Technologies

Phase A — Understand the business

Company Overview

POET Technologies is a pre-scale-revenue photonics design house built around one asset: the POET Optical Interposer™, a wafer-level platform that integrates electronic and photonic devices on a single chip using semiconductor-style packaging (the industry calls the general approach "wafer-level chip-scale packaging"). The pitch: eliminate the "costly components and labor-intensive assembly, alignment, and testing methods employed in conventional photonics," and thereby make optical engines cheaper and more scalable for AI data-centre interconnect.

What it actually sells today. Almost nothing, in revenue terms. FY2025 total revenue was $1,074,865 — against a $62.96M net loss. Revenue is recognised as (a) non-recurring engineering (NRE) milestone payments — sample products, design reports, test reports — and (b) early sample sales of optical engines. This is not a product business yet; it is a design-and-qualification business being funded by the equity market until (management hopes) production revenue arrives in 2026–27.

Product line: 100G LR4, 200G FR4, 400G/800G FR4 (Tx with integrated driver, Rx with integrated TIA), 1.6T 4×FR4 Rx, 200G/lane Tx & Rx for 1.6T and 3.2T, plus LightBar / Blazar™ C-Band and O-Band external light sources (the laser-source business management is prioritising for 2026).

Customers. The 20-F names no customer and books 100% of FY2025 revenue through the Asia (Singapore) entity. The named commercial relationships are all post-year-end: a $5M 800G production order (Oct 2025, Globe Newswire); a now-cancelled Marvell/Celestial AI relationship (Apr 2026); a Lumilens $50M initial PO / $500M-framework (May 2026); a "Lumilens/Lumilens-adjacent" pipeline management describes as "more than 10 active customer engagements expected to exceed $100M in future annual revenue". Note that several previously-touted partners (Foxconn, LITEON, Celestial/Marvell) are no longer active — see Lens 13.

Suppliers / manufacturing. Fab-light. POET divested its own fab (DenseLight, 2019) and now assembles/tests through Globetronics Manufacturing (GMSB) and NationGate Solution, both in Penang, Malaysia. It relocated out of China (dissolving the Super Photonics Xiamen JV with Sanan IC) explicitly to "mitigate the geopolitical risk in China." Some wafer/component suppliers are sole-source with no long-term contracts.

Bottom line for Lens 1: the moat claim is a manufacturing/integration-cost story on a large TAM; the P&L is a pre-commercial R&D burn. The gap between the two is the entire investment question.

Supply Chain

Map, upstream → POET → end demand, with the named links unless tagged:

• Upstream inputs: compound-semiconductor wafers (InP/GaAs for lasers, silicon for the interposer), lasers/PICs, TIAs, drivers, passive optics. POET calls out sole-source suppliers of wafers and components with no long-term agreements — a genuine chokepoint. Historically it designed its own hybrid laser ("Blazar") and previously used DenseLight (divested 2019) for laser fab.
• Contract manufacturing (the chokepoint POET controls): Globetronics (GMSB) — ~10,000 sq ft cleanroom, POET's wafer-level line installed, rated capacity 1 million optical engines/year. NationGate — light-source production line being installed. This Penang concentration is both the de-risking move (out of China) and a single-geography dependency.
• POET (design + assembly/test IP): ODIS (interposer designer, US), POET Technologies Singapore (PTS, design/test — 52 of ~80 employees), POET Optoelectronics Shenzhen, POET Malaysia (PTM). Exited: Super Photonics Xiamen (Sanan JV, winding up).
• Direct customer (who POET sells to): optical-transceiver module makers and light-source integrators — e.g. Lessengers (1.6T 2×DR4 module co-dev), Lumilens (EOI engines), and formerly Celestial AI (now Marvell). POET's stated strategy is to sell engines/light sources to module makers, and deliberately not compete with them on finished modules ("sell our optical modules, once developed, into niche rather than mainstream applications").
• End demand: hyperscale AI data centres (NVIDIA/AMD/Amazon-class buyers, referenced generically) pulling 800G today, 1.6T next, via pluggable transceivers and emerging CPO/NPO/LPO architectures.

Chokepoints: (1) sole-source wafer/laser suppliers with no contracts; (2) single Penang manufacturing cluster; (3) customer qualification — POET cannot swap suppliers/contract-manufacturers quickly because customers must re-qualify the line. This lens is not generic — the named links are real — but the whole chain is pre-volume, so "chokepoint" today means "single points of failure on a line that isn't yet running at scale."

Competitive Advantages (moats)

The claimed moat is process/IP: 79 issued patents + 34 applications (45 issued patents directly on the Optical Interposer), covering device structures, the underlying interposer technology, applications, and fabrication processes. Management frames the moat as "the full semiconductorization of the photonics industry" — wafer-level integration that competitors using discrete assembly cannot match on cost/scale.

How durable is it, honestly?

• IP + know-how: plausibly real but unproven in court and unmonetised. 79 patents is a respectable estate for a company this size, but patents on an integration approach are worth what the products they protect earn — and the products earn ~$1M/yr.
• Switching costs / design-in: the one genuine moat mechanic here. Optical engines get designed into a customer's module and qualified, which is sticky once it happens (management says the 800G Rx engine "was well received, fully qualified and has been designed into the optical transceiver modules of several customers during 2024 and 2025"). But the Marvell episode (Lens 13) shows that a design-in relationship can be severed overnight when it depends on trust, not volume commitments.
• Scale / network effects: none yet. POET is the sub-scale player. The 20-F itself concedes competitors "will be larger than we are and have significantly greater financial, marketing and other resources," with "large market capitalizations or cash reserves … better positioned to acquire".

Bargaining power: weak on both sides today. Suppliers are sole-source (they hold power); customers are large module makers and hyperscalers who can dual-source or vertically integrate (they hold power). POET's only lever is being early and cheap on wafer-level integration — a technology bet, not a structural moat. Verdict: the moat is a hypothesis (process cost + design-in stickiness), not yet a demonstrated one.

Segments

POET does not report product segments (it is effectively one pre-revenue segment). The only disaggregation in the 20-F is geography of revenue and geography of assets:

By the operating-segment note, all $1.07M of revenue is booked in the Asia (Singapore) entity; the US and Canada entities booked $0 revenue and carry the cost base (SM&A $25.1M split US $8.0M / Canada $11.8M / Asia $5.2M; R&D $18.1M, of which Asia $15.5M). $312.8M of the $328.6M total-asset book value sits in the Canada entity — i.e. it is the cash/short-term-investment pile, not operating assets.

Trend: revenue is directionally up (2024 was a near-zero trough because of the SPX/China wind-down), but the absolute numbers are noise. The only segment story that matters is the one that doesn't exist yet: 800G engines and light sources scaling in Asia in H2 2026. Q1 2026 revenue $503,389 (vs $166,760 PY) is the first data point on that curve.

---

Phase B — Measure performance

Earnings Result

FY2025 (audited, IFRS, the anchor):

• Revenue $1,074,865 (FY24 $41,427; FY23 $465,777).
• Operating expenses $43.17M — SM&A $25.08M, R&D $18.08M.
• Operating loss $(42.09M) (FY24 $(30.06M)).
• Net loss $(62.96M) / $(0.68) per share (FY24 $(56.70M)/$(0.94); FY23 $(20.27M)/$(0.51)). The gap between operating loss and net loss is almost entirely the $(25.28M) non-cash fair-value adjustment to the derivative warrant liability — a mark-to-market on foreign-currency-denominated warrants, not a cash cost.
• Cash used in operations $(31.09M); capexCapital expenditureMoney spent on long-lived things — buildings, machines, servers — rather than on running costs. $(2.26M); financing +$293.24M (equity, net).
• Balance sheet: cash $39.96M + short-term investments $273.44M = $313.40M liquid at 2025-12-31; total assets $328.57M; total equity $183.79M; accumulated deficit $(297.09M). Working capital $170.7M — but note that figure is after subtracting the $135.63M non-cash derivative warrant liability and $5.8M convertible debt.

Post-year-end (the numbers the market actually trades on):

• Q1 2026: revenue $503,389 (up from $166,760 PY; beat the ~$250K estimate), net loss $(12.3M) / $(0.08).
• Management upgraded FY2026 sales guidance to "at least $40M" and reiterated shipping >30,000 optical engines in 2026, with capacity to 1M units/month by end-2027.
• Cash ~$430M after $375M raised across Q4 2025 rounds + $150M in Jan 2026 + the $400M May 2026 registered-direct.

Read: the FY2025 P&L tells you nothing except "burning ~$30M/yr of cash, no revenue." The story is entirely forward: does the "≥$40M" 2026 guide print? Q1's $503K is <2% of $40M, so essentially the entire year is H2-loaded and unproven. The balance sheet is the good news — this is a funded pre-revenue company, not a distressed one.

Earnings Calls / Management Cadence (sentiment trend)

No transcripts on the shelf (transcripts/ empty; foreign filer, calls are less standardised). Sentiment reconstructed from 6-K press releases and the AGM recap:

• Late 2025: confident, order-driven — "$5M production order," Malaysia capacity coming online, "designed into several customers."
• Q1 2026 (Apr): the tone turned promotional and then catastrophic. CFO Thomas Mika's April 21 Stocktwits interview naming the Celestial AI relationship triggered Marvell's April 23 cancellation of all orders for alleged confidentiality breach — the stock fell ~45–47% on April 27. This is a management-communication failure of the first order.
• May–June 2026: aggressive recovery messaging — Lumilens $50M/$500M framework, $400M raise, AGM "production ramp on track, eyes 1M units/month," "10+ engagements > $100M.".

The recurring pattern in the language is the tell: large framework numbers ($500M, $100M, "1M units/month") attached to early-stage POs, announced into a retail audience, with a cadence of new "landmark partnerships" replacing lapsed ones. Management says "on track" a lot; it does not yet say "shipped at scale." Bears (Lens 13) read this as a promotion; bulls read it as a genuine pre-ramp company that over-shared once and got punished. The honest sentiment read: high promotional intensity, low delivered proof, one serious self-inflicted governance wound.

Comps

POET is not valuable on any earnings/sales multiple — FY2025 revenue is $1.07M and FY2026 guidance is "≥$40M," so P/E and even EV/Sales are meaningless (EV/Sales on the guide would be ~35x on a number that is 98% un-earned). It trades on option value — a ~$1.5B equity claim on a photonics possibility, with ~$430M of that backed by cash. The right frame is to place it against the optics peers that do have revenue, to show what "success" would have to look like:

Stock-Price Catalysts

52-week range $3.87 – $20.81, now ~$8.93 — a >5x peak-to-trough. What actually moves POET:

• Order / partnership announcements (up): $5M 800G PO (Oct 2025); Lumilens $50M/$500M framework, May 14 2026 — stock soared; Lessengers 1.6T co-dev (Mar 2026).
• Capital raises (down, dilution): the $400M registered-direct (May 2026) at $21.00/share — stock fell ~10% on dilution/warrant-overhang; multiple 2026 raises.
• The Marvell/Celestial cancellation (down, −45–47% on 2026-04-27) — the single largest move, on loss of the marquee customer + the confidentiality-breach narrative.
• Short reports (down): Wolfpack Research (Apr 2026, "obvious stock promotion," PFIC tax risk); Night Market Research ("Marvell isn't the only dead partnership… Lumilens next?").
• Litigation headlines (down/overhang): securities-fraud class action, lead-plaintiff deadline June 29 2026.

Pattern: POET is a pure narrative/retail stock — it reacts violently to (a) new "landmark" partnership PRs and (b) short/litigation/dilution shocks, and barely at all to fundamentals (there are none yet). ~51.8% of shares are held by US holders of record, 66,512 US record holders — a heavily retail register. This is a name where positioning and narrative, not numbers, set the price. That cuts both ways: enormous upside on a genuine ramp, brutal drawdowns on any crack in the story.

---

Phase C — Judge people & books

Management

• CEO & Chairman — Dr. Suresh Venkatesan (age 59, director since June 2015, ~11-yr tenure). Real pedigree: former SVP Technology Development at GlobalFoundries, before that Freescale/Motorola — a genuine semiconductor-process operator. He is the technical conviction behind the interposer.
• EVP & CFO — Thomas R. Mika (age 74, since Nov 2016) — long-time Tegal CFO. He is the individual whose April 21 2026 Stocktwits interview triggered the Marvell cancellation and the class action. Still in seat as of May 2026. For a company this dependent on customer trust, having the CFO cause the loss of the marquee account via a media appearance is a severe capital-allocation-of-credibility failure.
• President & GM — Vivek Rajgarhia (Lumentum/OpNext/GigOptix optics background) transitioned to "Corporate Development Advisor" (i.e. stepped out of the executive role) in 2026 — the 20-F officer table already flags "President (Resigned)". Losing your commercial/optics GM at the exact moment you're trying to prove commercialisation is a negative.
• Board: 6 directors, 5 independent. Lead independent director Jean-Louis Malinge is a genuine asset — former CEO of Kotura (silicon-photonics pioneer). Audit chair Robert Tirva (ex-IBM/Broadcom/Coherent SiC) appointed Dec 2024; prior audit chair Chris Tsiofas resigned June 27 2025.

Track record: 11 years, ~$297M accumulated deficit, and revenue still at $1M. That is either "patient deep-tech that is finally at the inflection" or "a company that has never commercialised." The bull needs the former; the history supports the skeptic.

Skin in the game — the red flag. After 11 years as CEO, Venkatesan directly owns just 7,500 common shares; all directors and officers combined own 128,715 shares (<1% of class). His economic exposure is almost entirely options (strikes largely $1.27–$1.79, deep in-the-money) — i.e. upside-only, no downside alignment. Meanwhile 2025 CEO comp was ~$6.94M (mostly a $6.0M equity award) on a company with $1M revenue. The one 5%+ holder is a hedge fund, MM Asset Management / MMCAP (1.53M shares + 12.96M warrants struck $4.26–$8.39) — a trading position, not a strategic anchor. No strategic/hyperscaler on the register.

Capital allocation: the defining competency here is raising money, not deploying it into returns — >$293M raised in 2025, ~$525M+ more across late-2025/2026, funding an R&D burn. Paying $8.2M/yr in "finance advisory fees" to a firm that helps them raise capital is itself a tell about where management energy goes. Archetype: founder-technologist CEO + promotional capital-markets machine. The technology leadership is credible; the capital-markets/communications posture is the liability.

Forensic Red Flags

Acting as a forensic analyst on the FY2025 IFRS statements:

• Revenue quality: revenue is immaterial ($1.07M) and largely NRE milestone recognition — inherently judgment-based (single vs. multiple performance obligations, output method). Low absolute risk because it's tiny, but the recognition policy is exactly the kind that gets aggressive once revenue scales — watch it in 2026–27.
• Derivative warrant liability — the big non-cash distortion: $135.63M liability at year-end, with a $(25.28M) P&L hit in FY2025. This is real (foreign-currency warrants remeasured through P&L) but it means ~40% of the reported net loss is non-cash mark-to-market. Cash burnCash burnHow much more cash goes out than comes in, per period. The clock on a company with no profits. ($31M ops) is the number that matters; the headline $63M loss overstates the operational bleed. Cuts both ways — investors under-appreciate that a rising share price makes this liability worse on the income statement.
• Going concern vs. $430M cash — the key nuance. The auditor (Marcum, for the FY2023 comparative) attached a going-concern emphasis — "substantial doubt about the Company's ability to continue as a going concernGoing concernAn auditor’s formal doubt that the company can fund itself for the next year. It is a warning about survival, not about performance.". But that language is a historical-losses artifact; as of the current balance sheet POET holds ~$430M cash and management states cash is "sufficient to fund operating and investing activities beyond one year," with ~$313M+ "remaining to be spent". Do not read the going-concern note as imminent insolvency — the real risk is dilution and commercialisation, not bankruptcy. At ~$31M/yr ops burn (call it $60–80M/yr as capex ramps), $430M is 5–10+ years of runway — an unusually well-funded pre-revenue name.
• Auditor turnover — yellow flag: Marcum LLP (2009–2023) → Davidson & Company LLP. An audit-firm change during a period of scaling losses and capital raises warrants a note (though the stated reason is routine and there is no restatement).
• Dilution — the single worst structural feature: shares went from 89.8M (end-2025) → 172.6M (May 2026) — +92% in ~5 months. Add warrant overhang: ~19M warrants at $26.15 (May raise), 22.9M Lumilens warrants at $8.25, 13M MMCAP warrants at $4.26–8.39, plus options. Fully-diluted count is materially above 172.6M. Every good-news PR is, in practice, funded by issuing more stock.
• SBC flattering nothing here (there is no non-GAAP EPS to flatter), but SBC is a real economic cost: $6.11M in FY2025, ~10% of the loss.

Regulatory findings (required sub-section):

• SEC EDGAR EFTS (Litigation Releases + AAERs): 0 findings naming POET Technologies, 2021–2026. Clean.
• 20-F Item 8 (Legal Proceedings — the foreign-filer equivalent of Item 3): management discloses no material active or pending legal proceedings as of the 20-F filing (2026-03-31).
• Post-filing (material — ): a securities-fraud class action was filed after the April 2026 events (class period April 1–27, 2026; lead-plaintiff deadline June 29, 2026), alleging (a) POET concealed likely PFIC status (adverse US-shareholder tax consequences) and (b) the confidentiality breach that led to Marvell cancelling all orders. Wolfpack Research and Night Market Research have published short theses. This is not SEC enforcement, but it is a live, material legal + reputational overhang.
• Net: clean on SEC enforcement history; not clean on live private securities litigation and short-seller scrutiny.

---

Phase D — Project & stress-test

Forward Projection

No our model forecast logged (watchlist rule; and I would not commit a base EPS on a company whose revenue is 98% un-earned). EPS is the wrong metric — POET will be loss-making for years regardless. The scoreable variable is FY2026 revenue vs. the "≥$40M" guide and the cash-runway-to-scale question.

Framing the three paths on revenue, not EPS, all inputs labelled:

• Base (~$25–40M FY2026 revenue) . Net loss widens toward ~$60–80M as manufacturing bring-up costs hit. Still burns cash; still ~$400M+ liquidity. Stock stays a narrative name.
• Bull (>$40M FY2026, on track to $100M+ FY2027) . This is the "becomes a real company" path — if 800G engines ship at volume and light sources ramp, POET re-rates toward the optics peer group (AAOI at ~19x EV/Sales on $507M — implying a much larger cap if revenue is real and durable). This is the entire long thesis.
• Bear (<$15M FY2026, guide missed) . Stock re-rates to cash value (~$430M / 172.6M ≈ ~$2.50/share of net cash, before further dilution) — i.e. >70% downside from ~$8.93 to hard book value. The floor is cash, and cash is being diluted.

The asymmetry is genuinely two-sided and wide: net cash is ~$2.50/share, the stock is ~$8.93, and the bull case is a multi-bagger. You are paying $6.40/share ($1.1B) for the option on commercialisation. Whether that option is cheap depends entirely on your probability that the "≥$40M → $100M+" ramp is real and not the eighth pivot.

Bull vs Bear

Bull case. POET is early on the single biggest hardware bottleneck in AI — moving from copper to optical interconnect — with a differentiated wafer-level integration platform, a real IP estate (79 patents), fully-qualified 800G engines already designed into customer modules, a Malaysia line rated at 1M engines/year, and — critically — ~$430M of cash to fund the ramp without a financing cliff. The Lumilens $50M PO / $500M framework and "10+ engagements > $100M" give a credible path to the "≥$40M FY2026 → $100M+ FY2027" story. If even half of that converts to shipped, durable revenue, POET re-rates toward peers trading at 19–42x sales — a multi-bagger from a ~$1.5B cap. The secular tailwind (AI-cluster optics market cited at ~$26B in 2026, +60% YoY ) is as strong as any in tech.

Bear case (2–3 permanent-impairment risks).

1. Commercialisation never arrives at scale. 11 years, $297M deficit, $1M revenue — the base rate for this company is non-commercialisation. The "≥$40M" guide is 98% unproven; a miss re-rates to ~$2.50 net cash.
2. Customer concentration + trust fragility. The Marvell/Celestial loss showed a marquee relationship can vanish overnight. Revenue is concentrated in a handful of un-named module makers; any one defection is a >30% stock move.
3. Relentless dilution is the business model. +92% shares in 5 months; every PR funded by issuance. Even if the product works, per-share value can be diluted away — the equity is a worse asset than the enterprise.

Pre-mortem (it's Jan 2028, thesis broke): FY2026 revenue came in ~$12M (guide missed on qualification slippage), Lumilens' PO never converted to volume (framework was non-binding), a second short report + the class action settled badly, POET raised again at a lower price to fund the burn, and the stock sits near net cash ~$2. The tell was always there: framework numbers, not shipped numbers.

Are multiples too high? There are no multiples — it's an option. The option premium (~$1.1B over cash) is rich for a pre-revenue name with this litigation/dilution profile, but not absurd given the TAM if you assign even ~20–30% odds to the bull.

Contrarian view (what the market is refusing to see): cuts both ways. Bulls refuse to see that this is a promotional, serially-diluting, litigation-scarred shell with a CFO who cost them their best customer. Bears refuse to see that it is genuinely well-funded ($430M is real, runway is long) and that the technology and the design-ins are real, not fabricated — a rare pre-revenue name that will not be forced to sell the story at a fire-sale price. The truth is it's both a real asset and a bad stock, and which one wins is decided by the FY2026 revenue print.

Devil's Advocate (short-seller)

You are dismantling the bull case. The short case here is unusually well-developed because two funds have already written it:

• "Obvious stock promotion" (Wolfpack). Seven business pivots this decade; a cadence of "landmark partnerships" that lapse and get replaced. Night Market's thesis is blunter: "Marvell isn't the only dead partnership. Foxconn, LITEON and more are too. Lumilens next? Appears a recycled and hollow incestuous promotion." The pattern-matching to a pump-and-dilute machine is the core short.
• Where revenue is "concentrated": it isn't — there basically isn't any. $1.07M FY2025, and the named customers keep changing. A short says the "10+ engagements > $100M" and "$500M framework" are non-binding future-tense numbers designed to move a retail stock, not backlog.
• The moat is weaker than bulls think: the 20-F itself concedes competitors are larger, better-capitalised, and could vertically integrate or acquire the technology away. NVIDIA/Broadcom/Marvell/Coherent/Lumentum are the CPO ecosystem; NVIDIA is investing in Lumentum and Coherent for laser supply — POET is not in that inner circle.
• The most dangerous competitor bulls underestimate: not a single rival — it's the customers' own vertical integration plus Ayar Labs (closed a $500M Series E at $3.75B, AMD/NVIDIA-backed, March 2026 ), which is far better funded and strategically anchored than POET on the same optical-I/O bet.
• Worst capital-allocation / governance: CEO owns 7,500 shares after 11 years; $6.9M comp on $1M revenue; $8.2M/yr to a capital-raising advisor; CFO cost the company its marquee customer via a media interview; a live securities-fraud class action (PFIC concealment + confidentiality breach). President/GM stepped out during the ramp.
• What must hold for ~$8.93: that FY2026 revenue prints ≥$40M and is durable and dilution stops and no further customer defects and the litigation is immaterial. That is a long conjunction.
• Growth disappoints 20–30%: irrelevant framing — if the guide is missed at all, the stock re-rates to net cash ~$2.50 (a >70% drawdown), because there's no earnings floor, only a cash floor.
• Single scenario that permanently impairs: a second marquee-customer loss or a Lumilens non-conversion, combined with a down-round raise — turning "well-funded optionality" into "diluting a dying story." Plausibility: moderate. The base rate (11 years, no commercialisation) is the short's best friend.

Management Questions (ordered by information value)

1. Of the "≥$40M" FY2026 revenue guide, how much is firm purchase orders with delivery dates vs. framework/NRE/forecast — and what is the H1/H2 split? (The whole thesis lives here.)
2. Walk through the Lumilens $50M PO: is it a binding, delivery-scheduled order, or contingent on development/qualification milestones? What has actually shipped and been paid to date?
3. What exactly happened with Marvell/Celestial — has any relationship survived, and what specific process/governance change now prevents a CFO interview from voiding a customer contract again?
4. Given ~172.6M shares after +92% dilution in five months, what is the fully-diluted count including all warrants/options, and what is your explicit issuance plan for the next 24 months? At what point do you stop diluting?
5. On the PFIC class-action claim — is POET a PFIC for 2025/2026, and what is management's remediation for US shareholders?
6. After 11 years, why does the CEO own only 7,500 common shares outright? Will management commit to open-market purchases to align with holders?
7. How many of the "10+ active engagements > $100M" have signed POs vs. NDAs/LOIs? Name the number at each stage.
8. What is the gross margin on the first 800G engines shipping in H2 2026, and the path to a positive gross margin at the 1M-units/month capacity?
9. Which inputs are sole-source with no long-term contract, and what is the second-source plan before you scale to volume?
10. What is the true cash burn guide for 2026–27 (ops + capex), and at $430M cash, what is the runway to cash-flow breakeven under the base plan?
11. Why the auditor change (Marcum → Davidson), and were there any disagreements on accounting/controls?
12. The derivative warrant liability is $135M and hits the P&L as the stock rises — will you restructure to CAD/USD-consistent warrants to remove this distortion?
13. Why did the President/GM step out to an advisory role during the commercial ramp, and who now owns commercial execution?
14. What is the defensible moat against a customer (or NVIDIA/Broadcom) vertically integrating wafer-level optical engines, beyond the patent estate?
15. What single 2026 milestone would you stake the thesis on, and what happens to the plan if it slips two quarters?

---